PCM
RGLS

Prelude Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Prelude Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,100
Closed -$25.2K – 1497
2024
Q2 		$25.2K Sell
14,100
-118,370
-89% -$275K ﹤0.01% 1171
2024
Q1 		$382K Buy
132,470
+92,210
+229% +$150K 0.02% 766
2023
Q4 		$51.5K Hold
40,260
– – ﹤0.01% 1073
2023
Q3 		$55.2K Sell
40,260
-400
-1% -$580 ﹤0.01% 1040
2023
Q2 		$59.8K Buy
+40,660
New +$54.2K ﹤0.01% 964
2016
Q2 		– Sell
-6
Closed -$5K – 1710
2016
Q1 		$5K Buy
+6
New +$4.77K ﹤0.01% 1199
2015
Q3 		– Sell
-2
Closed -$2K – 1733
2015
Q2 		$2K Buy
+2
New +$3.23K ﹤0.01% 1645

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return